| Wall Street Analysts See a 63.23% Upside in AngioDynamics (ANGO): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 63.2% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-04-28 14:56:03 |
Czytaj oryginał (ang.) |
| Is AngioDynamics (ANGO) Outperforming Other Medical Stocks This Year? |
Here is how AngioDynamics (ANGO) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year. |
zacks.com |
2025-04-11 14:45:36 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 68.28%: Read This Before Placing a Bet |
The average of price targets set by Wall Street analysts indicates a potential upside of 68.3% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-04-07 14:55:34 |
Czytaj oryginał (ang.) |
| AngioDynamics price target raised to $16 from $15 at H.C. Wainwright |
H.C. Wainwright raised the firm's price target on AngioDynamics to $16 from $15 and keeps a Buy rating on the shares. The company reported a beat in fiscal Q3 and raised its fiscal 2025 guidance, the analyst tells investors in a research note. |
https://thefly.com |
2025-04-07 10:06:04 |
Czytaj oryginał (ang.) |
| AngioDynamics Stock Up on Q3 Earnings Beat, Gross Margin Expands |
ANGO reports solid fiscal third-quarter earnings with continued strength in its Med Tech segment. The expansion of gross margin bodes well. |
zacks.com |
2025-04-03 18:15:54 |
Czytaj oryginał (ang.) |
| Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance |
AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the consensus for a per-share loss of 13 cents. |
benzinga.com |
2025-04-02 14:41:46 |
Czytaj oryginał (ang.) |
| AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript |
AngioDynamics, Inc. (NASDAQ:ANGO ) Q3 2025 Earnings Conference Call April 2, 2025 8:00 AM ET Company Participants Jim Clemmer - President & CEO Stephen Trowbridge - EVP & CFO Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Eduardo Martinez - H.C. Wainwright Operator Good morning, and welcome to the AngioDynamics Fiscal Year 2025 Third Quarter Earnings Call. |
seekingalpha.com |
2025-04-02 14:20:30 |
Czytaj oryginał (ang.) |
| AngioDynamics (ANGO) Tops Q3 Earnings and Revenue Estimates |
AngioDynamics (ANGO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.16 per share a year ago. |
zacks.com |
2025-04-02 12:40:36 |
Czytaj oryginał (ang.) |
| AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025. Fiscal Year 2025 Third Quarter Highlights Quarter Ended February 28, 2025 Pro Forma* YoY Growth Pro Forma* Net Sale. |
businesswire.com |
2025-04-02 10:30:00 |
Czytaj oryginał (ang.) |
| AngioDynamics to Host Virtual Cardiovascular Investor Event |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, will host a virtual cardiovascular investor event this Wednesday, April 2, 2025 at 9:00am ET. The event will take place immediately following the Company's Fiscal 2025 Third Quarter Financial Results Conference Call which wil. |
businesswire.com |
2025-03-31 12:00:00 |
Czytaj oryginał (ang.) |
| AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into th. |
businesswire.com |
2025-03-19 10:00:00 |
Czytaj oryginał (ang.) |
| AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Oppenheimer 35th Annual Healthcare MedTech and Service. |
businesswire.com |
2025-03-10 18:30:00 |
Czytaj oryginał (ang.) |
| ANGO Stock Looks Promising on New Ischemia Study for Auryon System |
AngioDynamics initiates the AMBITION BTK RCT and registry to advance treatment for patients with chronic limb-threatening ischemia and below-the-knee peripheral artery disease. |
zacks.com |
2025-01-31 12:11:31 |
Czytaj oryginał (ang.) |
| AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the start of a Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Criti. |
businesswire.com |
2025-01-30 09:30:00 |
Czytaj oryginał (ang.) |
| AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares |
AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins, boosting confidence in achieving high single-digit revenue growth and double-digit EBITDA margins in time. Clinical data for AlphaVac and NanoKnife were positive relative to established standards of care, suggesting potentially competitive offerings in the pulmonary embolism and prostate cancer markets if management can execute. Auryon, AlphaVac, and NanoKnife all offer double-digit growth potential, but sales execution against larger entrenched rivals is not going to be easy and the Med Device business offers limited potential. |
seekingalpha.com |
2025-01-16 07:07:22 |
Czytaj oryginał (ang.) |
| AngioDynamics price target raised to $15 from $12 at Canaccord |
Canaccord raised the firm's price target on AngioDynamics to $15 from $12 and keeps a Buy rating on the shares. AngioDynamics reported one of its strongest quarters in recent memory, the analyst tells investors in a research note. The firm back-end loaded its NanoKnife expectations for this fiscal year, but thinks in the long-term it could provide significant growth for AngioDynamics. It sees thrombectomy acceleration today with improving profitability. |
https://thefly.com |
2025-01-09 13:07:01 |
Czytaj oryginał (ang.) |
| AngioDynamics Stock Up on Q2 Earnings Beat, Gross Margin Declines |
ANGO registers overall strong top-line results on a pro-forma basis in second-quarter fiscal 2025, driven by strength in the Med Tech business. |
zacks.com |
2025-01-09 12:51:18 |
Czytaj oryginał (ang.) |
| AngioDynamics: A Surgical Approach To Market Growth |
AngioDynamics, Inc.'s Q2 2025 earnings beat expectations, with non-GAAP EPS at -$0.04 and revenue at $73.02 million, driving a 35% stock surge. Med Tech division shines, with 25% revenue growth and key products like Auryon, AlphaVac, and AngioVac showing strong performance and market acceptance. NanoKnife's FDA clearance and promising clinical trials highlight its potential in prostate cancer treatment, contributing to a 23.1% rise in disposable revenue. |
seekingalpha.com |
2025-01-08 19:15:55 |
Czytaj oryginał (ang.) |
| AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript |
AngioDynamics, Inc. (NASDAQ:ANGO ) Q2 2025 Earnings Conference Call January 8, 2025 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Stephen Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants John Young - Canaccord Genuity Steven Lichtman - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning and welcome to the AngioDynamics Fiscal Year 2025 Second Quarter Earnings Call. |
seekingalpha.com |
2025-01-08 13:00:42 |
Czytaj oryginał (ang.) |
| AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates |
AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago. |
zacks.com |
2025-01-08 10:45:35 |
Czytaj oryginał (ang.) |
| AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2025, which ended November 30, 2024. Fiscal Year 2025 Second Quarter Highlights Quarter Ended November 30, 2024 Pro Forma* YoY Growth Pro Forma* Net Sa. |
businesswire.com |
2025-01-08 08:30:00 |
Czytaj oryginał (ang.) |
| AngioDynamics to Present at the J.P. Morgan Healthcare Conference |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at 7:30. |
businesswire.com |
2025-01-06 11:26:00 |
Czytaj oryginał (ang.) |
| AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that the Company will host a virtual investor event on Wednesday, January 8, 2025 at 9:30am ET. This event will take place following the previously announced Fiscal 2025 Second Quarter Financial Results Confer. |
businesswire.com |
2025-01-06 11:25:00 |
Czytaj oryginał (ang.) |
| AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market open on Wednesday, January 8, 2025, followed by a Virtual NanoKnife System investor event. Fiscal 2025 Second Quarte. |
businesswire.com |
2024-12-19 19:00:00 |
Czytaj oryginał (ang.) |
| ANGO Stock Up Post FDA Nod for Prostate Tissue Ablation With NanoKnife |
AngioDynamics' latest regulatory approval is likely to pave the way for an alternative to conventional radical surgery and improve patient outcomes. |
zacks.com |
2024-12-10 14:15:19 |
Czytaj oryginał (ang.) |
| Strength Seen in AngioDynamics (ANGO): Can Its 23.3% Jump Turn into More Strength? |
AngioDynamics (ANGO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-12-10 12:30:37 |
Czytaj oryginał (ang.) |
| AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NanoKnife System for prostate tissue ablation. The Company received clearance for the NanoKnife System for prostate tissue ablation follow. |
businesswire.com |
2024-12-09 08:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 94.32%: Here's is How to Trade |
The consensus price target hints at a 94.3% upside potential for AngioDynamics (ANGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-01 12:56:08 |
Czytaj oryginał (ang.) |
| AngioDynamics Stock Plunges 13.8% in Three Months: What's Next? |
ANGO enhances its offerings and expands the breadth of its products and services. However, macro challenges are likely to continue to hurt its performance. |
zacks.com |
2024-10-29 13:46:09 |
Czytaj oryginał (ang.) |
| ANGO Stock Rises Following the Receipt of CPT Category I Code for IRE |
AngioDynamics announces the receipt of CPT Category I code for IRE technology. |
zacks.com |
2024-10-23 17:36:09 |
Czytaj oryginał (ang.) |
| AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2024-10-08 14:35:31 |
Czytaj oryginał (ang.) |
| AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise |
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business. |
zacks.com |
2024-10-04 16:47:24 |
Czytaj oryginał (ang.) |
| Here's Why You Should Add AngioDynamics Stock to Your Portfolio |
ANGO shows growth potential with its NanoKnife system and expanding U.S. sales but faces challenges from pricing pressure and macroeconomic factors. |
zacks.com |
2024-10-03 15:40:15 |
Czytaj oryginał (ang.) |
| Why AngioDynamics Stock Is Crashing Today |
Investors didn't like the medical technology company's fiscal 2025 Q1 update. |
fool.com |
2024-10-03 15:23:22 |
Czytaj oryginał (ang.) |
| AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday |
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday. |
benzinga.com |
2024-10-03 14:02:05 |
Czytaj oryginał (ang.) |
| AngioDynamics (ANGO) Reports Q1 Loss, Misses Revenue Estimates |
AngioDynamics (ANGO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.12 per share a year ago. |
zacks.com |
2024-10-03 12:41:07 |
Czytaj oryginał (ang.) |
| AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2025, which ended August 31, 2024. Fiscal Year 2025 First Quarter Highlights Quarter Ended August 31, 2024 Pro Forma* YoY Growth Net Sales $67.5 million. |
businesswire.com |
2024-10-03 10:30:00 |
Czytaj oryginał (ang.) |
| Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings |
AngioDynamics, Inc. ANGO will release earnings results for its first quarter, before the opening bell on Thursday, Oct. 3. |
benzinga.com |
2024-10-03 07:37:09 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for September 30th |
MRX, ANGO, OPRA, ATAT and PAM have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2024. |
zacks.com |
2024-09-30 12:05:22 |
Czytaj oryginał (ang.) |
| ANGO Initiates RECOVER-AV Trial for AlphaVac F1885 in Europe |
AngioDynamics' RECOVER-AV trial evaluates the AlphaVac F1885 System's safety and efficacy in treating acute pulmonary embolism in Europe. |
zacks.com |
2024-09-23 14:36:15 |
Czytaj oryginał (ang.) |
| AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the launch of the Prospective, Multicenter, Multi-national, Single Arm Trial Evaluating the Efficacy, Safety and long term functional outcomes of percutaneous mechanical aspiration thrombectomy for Treatment of Acut. |
businesswire.com |
2024-09-19 20:40:00 |
Czytaj oryginał (ang.) |
| AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024 |
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market open on Thursday, October 3, 2024. The Company's management will host a conference call at 8:00 am ET the same day to. |
businesswire.com |
2024-09-19 12:00:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for September 13th |
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024. |
zacks.com |
2024-09-13 12:16:07 |
Czytaj oryginał (ang.) |